


# Open Innovation Hub for Drug Discovery and Development

## Process for drug discovery and development



< Core facilities in KBIC >

Program proposal  
for establishment of a center for drug  
discovery and development

- Propose to pharmaceutical companies in Japan and abroad a program that clusters and consolidates research functions of R&D institutions in KBIC, including infrastructure
- Dedicated coordinators conduct a follow-up to tackle the realization of innovative drug discovery and development through industrial - academic - government collaborations.


One stop service coordinating  
a necessary drug discovery/development environment

“Researchers” “Facilities” “Clinical environment”

Number of proposed companies: 51

Joint research contracts: 5

\* Including 1 pilot study



## (1) Drug discovery/development for autoimmune diseases and cancer

**[Institutions participating in joint research]**

Meiji Seika Pharma, FBRI

**[Research theme]**

Treat inflammatory diseases including autoimmune diseases using anti-PD-1 immunosuppression activity



Meiji Seika ファルマ株式会社

## (2) Development of new treatments for retinal diseases

**[Institutions participating in joint research]**

Santen Pharmaceutical, RIKEN, FBRI

**[Research theme]**

Drug discovery/development research in ophthalmic disorders using iPS cells



## (3) (Undisclosed program)

**[Institutions participating in joint research]**

Nissan Chemical, Kobe University, FBRI

**[Research theme]**

(Undisclosed)



## (4) Development of technologies for diagnosing immunological diseases

**[Institutions participating in joint research]**

Sysmex, Kyoto University, FBRI

**[Research theme]**

Establish new analytic method and develop an early diagnostic system for immune functions

